Clinical Trial: Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Comparative Treatment of Intravitreal Bevacizumab and Triamcinolone Acetonide on Diabetic Macular Edema

Brief Summary: One of the most frequent complications of diabetic retinopathy is diabetic macular edema. Recently, intravitreal bevacizumab and intravitreal triamcinolone were the most popular therapeutic modalities. However, as the long term effects of intravitreal bevacizumab and intravitreal triamcinolone on visual acuity and macular thickness have not been compared, it was the purpose of the present study to compare these treatment effects

Detailed Summary: Randomization of intravitreal bevacizumab, intravitreal triamcinolone, intravitreal bevacizumab with triamcinolone on eyes with diabetic macular edema
Sponsor: Hallym University Medical Center

Current Primary Outcome: Visual acuity [ Time Frame: baseline, 1 month, 3 months, 6month, 9 month, 12 month ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Central macular thickness [ Time Frame: baseline, 1 month, 3 months, 6 months, 12months ]

analyzed by optical coherence tomography


Original Secondary Outcome: Same as current

Information By: Hallym University Medical Center

Dates:
Date Received: April 25, 2011
Date Started: March 2009
Date Completion:
Last Updated: April 26, 2011
Last Verified: March 2009